What Are Orphan Drugs?

The Food and Drug Administration (FDA) defines a rare disease as one which affects fewer than 200,000 individuals in the United States or one which affects more than 200,000 individuals but is unlikely to generate specific revenue to recover drug development costs. Despite the fact that 25 million Americans are affected by one or more of the 6,000-8,000 known rare diseases, the latter clause of this definition has caused said diseases to be underserved in the pharmaceutical marketplace for much of history. Drug development efforts by pharmaceutical companies were primarily focused on blockbuster therapies targeting larger patient populations. 

Though public service drugs designed to treat rare patient populations were long produced at a financial loss, increasingly stringent FDA regulatory requirements made continued production unsustainable. Factors ranging from increased clinical trial costs to intra-company competition and healthcare reforms also placed a limited market potential on rare diseases that further discouraged investment. This production environment would see treatments for some rare diseases discovered incidentally during development of widely usable drugs, but intentional drug development efforts for rare diseases were often abandoned due to limited financial incentives and insufficient funding. These abandoned treatments eventually become known as orphan drugs.

The passage of the 1962 Kefauver-Harris Amendments also hindered the availability of treatments for rare diseases. Inspired by the wave of congenital birth defects in the 1950s and 1960s among children whose mothers used the morning sickness cure thalidomide, the laws sought to strengthen drug safety and efficacy requirements so that users’ health wouldn’t be compromised by unforeseen side effects. These protections made medicine safer for consumers but caused drug development to become a more costly process. This made companies more reluctant to create treatments for rare diseases unless they could yield tangible returns on investment. 

In 1983, Congress passed the Orphan Drug Act, which allowed the government to provide incentives for companies to develop orphan drugs. The Act encourages pharmaceutical companies to invest in research and development for rare disease treatments through a framework which lets the FDA grant orphan drug designation to eligible products. Orphan designation entitles drug makers to benefits such as tax credits, waived regulatory fees, and seven years of market exclusivity for the drug itself. Market exclusivity refers to a special protection that stops other companies from selling another version of the same drug. Implementation of the Act has led to extensive success over the years, but concerns about rare disease and drug development persist because 95% of rare disease patients still lack sufficient access to approved treatments for their condition.

Arguments In Favor of the Orphan Drug Act

Policymakers and advocates who support the Orphan Drug Act highlight its benefits for disease awareness, treatment availability, and innovation. They believe the Act’s provisions must continue uninterrupted in order to grant patients better healthcare outcomes and force pharmaceutical companies to stay accountable to patient wellbeing over profit.

Stimulates Rare Disease Innovation

The development and distribution of orphan drugs has allowed companies to improve synthesis procedures and find more effective ways to provide end users with cutting-edge treatments. One such initiative is the administration of decentralized clinical trials, which study the effects that tested medications have on patients through wearable technology like watches and phones. Data from these devices is processed and entered into telemedicine hubs, making it easier for researchers to gather participants from different geographical regions and walks of life. This technique, in turn, breeds a more holistic understanding of a given drug’s effects. On the production side, requirements established by the Act’s framework allow pharmaceutical companies to repurpose drugs that have already been approved for other indicators so that they can treat a given rare disease. This allows them to reduce the time and cost typically required for drug production while ensuring that an effective final product enters the market. 

The awareness of rare diseases created by the Orphan Drug Act have also given rise to robust nongovernmental organizations and patient registries committed to bettering the treatment outcomes of afflicted populations through lobbying. Organizations manifest these improvements by pushing for policy changes and expanded research funding for rare diseases and drug creation. Their advocacy acts as a valuable counterpoint for limited policymaker recognition of rare diseases’ impact and an insufficient prioritization of rare diseases relative to other issues. Patient registries supplement this work by logging data on long term outcomes and disease prevalence which aids in the development of successive treatments. 

Expands Treatment Availability

Prior to the ODA’s passing, there were only 10 orphan drugs available for use in combating rare diseases. As of 2015 FDA intervention has given rise to 3,600 orphan drug designations and 550 newly approved orphan drugs. These therapies target a combination of 227 known rare diseases from cancers to bleeding disorders and infections, with most new drugs being used for cancer treatment. Research prompted by the Act has also cleared the way for secondary induction approvals to increase from 19% in the 1980s to 47% in the 2010s.  numbers of secondary induction approvals. These clearances allow drugs devised for one medical condition to be used in treating another, allowing medicines already on the market to have an even greater effect. Changing drug development in the United States as the result of the Act’s implementation also influenced changes in regions such as Japan, Europe, Singapore and Australia, ensuring that patients around the world can continue to benefit from a variety of care options. 

Encourages Public–Private Partnerships

The collaboration between public-Private partnerships (PPP), provides an additional source of funding for orphan drug development. These partnerships unite pharmaceutical companies, government agencies, and philanthropic agencies to share the risks and cost inherent in formulating new therapies. An example of a PPP is the philanthropy model of the Cystic Fibrosis Foundation, which played a crucial role in several breakthrough therapies for the disease. With the backing of family members who didn’t want to lose loved ones, the Foundation invested $40 million with Vertex Pharmaceuticals to launch molecular studies into the root cause of cystic fibrosis. These studies would be refined throughout the 2010s as more drug companies contributed capital funding and scientific capabilities, yielding the drugs Kalydeco, Orkambi, Symdeco, and a fusion of all three known as Trikafta. Each of these drugs was built to attack the identified root causes and made it possible for patients of all subtypes to receive quality treatment. Most PPPs function the same way, blending capital funding with advocacy from those familiar with a given condition to create long-lasting gains for patient populations.

Arguments Against the Orphan Drug Act

Opponents of the Orphan Drug Act contend that the act has only worsened the problems which it was put in place to solve. Their arguments point to such issues as the high prices set by market exclusivity agreements, which often prevent patients from affording the best of a limited number of options. They also highlight the lack of spending allotted to orphan drugs as a means to pad the product’s profit margin, and the misuse of company incentive policies to reap multiple benefits from the same product. All of these effects could combine to result in even more issues serving patient populations that are already in need. 

High Drug Prices and Affordability Challenges

Though the ODA’s stated goal is improving access and cost to therapeutic treatments for rare diseases, the exorbitant cost of orphan drugs leaves patients unable to afford available treatment options. This high price is primarily due to the FDA granting extended market exclusivity status to individual drug developers. Because the FDA cannot approve an additional application for a given disease indication during an extended orphan drug market exclusivity period, companies are unable to have existing wares approved for the treatment of rare diseases. Developers are then unable to field more cost-effective alternatives to treatments and force patients to find a way to pay high costs or else go without any intervention in disease progression.  Products with attached orphan drug designations also draw concern because of how much more expensive they are per year than those without designation. A 2021 study placed this difference at an average of $218,872 annually per patient for drugs with an orphan indication, compared to an annual average of $12,798 for drugs without.

Misuse of Incentives

The ODA’s incentivization process has been criticized for giving pharmaceutical companies a disproportionate focus on orphan drug development. Applying for orphan drug approval gives pharmaceutical companies the chance to avoid costs corresponding to non-orphan drug applications. If this process is a success, the resulting market exclusivity agreements let them set the designated price for any applicable orphan drug. Because these prices tend to be high enough that investment in developing the drug is rewarded, they end up limiting patient treatment options in the absence of generic medication. Policy stakeholders have also reported instances of manufacturers obtaining several orphan drug designations and incentives for the same drug product or for drugs already on the market to treat more prevalent conditions. A 2024 study on these incidents found that 100 of the 491 novel orphan drugs approved between 1990 and 2022 were designated for both common and rare diseases, with 34 of those approvals happening in 2021. Though the ODA was meant to lend profitability to orphan drug production, these incidents suggest that its policies can be abused to the  manufacturers’ benefit. 

Limited R&D Spending and Patient Access Concerns

The limited market potential for rare disease treatments deters pharmaceutical companies from investing as many resources in them as they do treatments for common diseases. This is partially because research and development expenditures per orphan drug are lower than non-orphan comparators, often relying on smaller or single pivotal trials when assessing the new drug’s safety. Market exclusivity and smaller populations then combine to create high drug prices and high company profits when stacked against minimal orphan expenditures. The frequency with which this relationship recurs creates ethical concerns regarding the appropriation of healthcare resources. Contributing heavily to research centered on smaller populations risks diverting funding from more prevalent health challenges, creating an environment where the financial incentives allocated for research and development shift research priorities to commercially sustainable diseases. 

The difficulty posed when accessing patients for orphan drug clinical trials has also begun to cast doubt on the treatments which result from them. Changing protocol definitions have caused the population that can be considered to have a rare disease to fall below 200,000 individuals in the U.S. and 5 in 10,000 in the EU. This shift has made it more difficult to recruit adequate numbers of patients for clinical trials and prevents randomized controlled trials (RCTs) from being suitable procedure because it affects the balance of patients available to be part of each group. RCTs are also difficult to implement in some rare disease trials because of ethical concerns with creating a placebo group. Such fundamental compromises of testing conditions can make it difficult for studies to produce statistically significant results.  

Recent Progression of Orphan Drug Legislation

Price issues resulting from the incentives that the ODA provides drug companies have inspired Congressional remedies that make orphan-designated products more affordable to patients who need them. Established in 2022, the Medicare Drug Price Negotiation Program authorizes the Centers for Medicare & Medicaid Services to negotiate prices for select high-spending drugs covered under Medicare Parts B and D. The program began with 10 single-source drugs for 2026 and is scheduled to double this coverage by 2029. Although orphan drugs were initially excluded from eligibility, concerns that this exclusion could continue to discourage research and development for rare disease indications caused lawmakers to introduce the ORPHAN Cures Act in 2025. This legislation seeks to preserve incentives for orphan drug development by extending exemption protections to certain drugs approved for multiple rare disease indications. Doing so allows these treatments to find new markets among those who couldn’t previously afford them.

Conclusion

The Orphan Drug Act has significantly expanded research, development, and treatment options for rare diseases by creating incentives for pharmaceutical investment in historically underserved patient populations. While the Act has increased the availability of orphan drugs, concerns about affordability, access, and the long-term impact of current incentive structures remain considerations for policymakers. As rare disease diagnoses continue to increase, they must balance the need to sustain innovation with efforts to promote patient access and responsible use of healthcare resources. Ongoing evaluation of orphan drug policies will be important to ensuring that the benefits of scientific advancement are sustainable and accessible to populations they intend to serve.

Frequently Asked Questions